1 Department of Otorhinolaryngology and Laryngological Oncology in Zabrze, Medical University of Silesia in Katowice, Zabrze 41-800, Poland.
2 Department of Microbiology and Immunology in Zabrze, Medical University of Silesia in Katowice, Zabrze 41-808, Poland.
Exp Biol Med (Maywood). 2018 May;243(9):762-769. doi: 10.1177/1535370218774539.
An increasing number of patients with parotid gland tumors have been observed in recent years. The relationship between the immune system and tumor formation is thoroughly investigated. However, newly discovered molecules offer a new insight into the pathophysiology of malignancies. It would be ideal to find an easily determinable biomarker of tumor existence, its malignant potential or a biomarker suggesting the probability of disease recurrence. Our study is the first to examine serum concentrations of IL-33 and its sST2 receptor in patients with various types of parotid gland tumors. Serum IL33, sST2, IL-4 and IL-10 concentrations were determined in patients with benign and malignant parotid gland tumors (pleomorphic adenoma, Warthin's tumor, myoepithelioma and acinic cell carcinoma). We observed for the first time that serum IL-33 level was significantly elevated in patients with various types of parotid gland tumors and sST2 levels were significantly higher in pleomorphic adenoma and acinic cell carcinoma patients compared to the controls. Our results demonstrate for the first time that serum IL-33 and its sST2 receptor may be important factors in the pathology of parotid gland tumors. Although our results are promising, further investigations are required to detect if serum concentrations of those molecules may be a biomarker in parotid gland tumors. Impact statement Parotid gland tumors seem to be an increasingly important medical challenge, mostly due to a noticeable increase in the incidence. It would be crucial to find an easily determinable biomarker of tumor existence, its recurrence or malignant potential. We observed for the first time that serum IL-33 level was significantly elevated in patients with various types of parotid gland tumors and its sST2 receptor levels were significantly higher in pleomorphic adenoma and acinic cell carcinoma patients compared to the controls. We believe that our study helps to understand the biology of the tumors and a potential role of a relatively newly identified cytokine IL-33 in the pathophysiology of the parotid gland tumors.
近年来，观察到越来越多的腮腺肿瘤患者。免疫系统与肿瘤形成之间的关系得到了彻底研究。然而，新发现的分子为恶性肿瘤的病理生理学提供了新的见解。理想情况下，我们希望找到一种易于确定的肿瘤存在、其恶性潜能或疾病复发概率的生物标志物。我们的研究首次检查了各种类型腮腺肿瘤患者的血清中 IL-33 及其 sST2 受体的浓度。在患有良性和恶性腮腺肿瘤（多形性腺瘤、Warthin 瘤、肌上皮瘤和腺泡细胞癌）的患者中确定了血清 IL33、sST2、IL-4 和 IL-10 浓度。我们首次观察到，各种类型腮腺肿瘤患者的血清 IL-33 水平显著升高，与对照组相比，多形性腺瘤和腺泡细胞癌患者的 sST2 水平显著升高。我们的结果首次表明，血清 IL-33 及其 sST2 受体可能是腮腺肿瘤病理学的重要因素。尽管我们的结果很有希望，但需要进一步研究以检测这些分子的血清浓度是否可以作为腮腺肿瘤的生物标志物。
